Cargando…

ABTB2 Regulatory Variant as Predictor of Epirubicin-Based Neoadjuvant Chemotherapy in Luminal A Breast Cancer

Background: Epirubicin combined with docetaxel is the cornerstone of neoadjuvant chemotherapy (NAC) for breast cancer. The efficacy of NAC for luminal A breast cancer patients is very limited, and single nucleotide polymorphism is one of the most important factors that influences the efficacy. Our s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gong, Yajie, Hu, Nanlin, Ma, Li, Li, Wentong, Cheng, Xiang, Zhang, Yi, Zhu, Ying, Yang, Yang, Peng, Xiating, Zou, Danyi, Tian, Jianbo, Yang, Lan, Mei, Shufang, Wang, Xiaoyang, Lo, Chun-han, Chang, Jiang, Hou, Tieying, Zhang, Hong, Xu, Binghe, Zhong, Rong, Yuan, Peng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545368/ https://www.ncbi.nlm.nih.gov/pubmed/33102228 http://dx.doi.org/10.3389/fonc.2020.571517

Ejemplares similares

Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel
por: Li, Qian, et al.
Publicado: (2014)

Correction: Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel
por: Li, Qian, et al.
Publicado: (2015)

AWESOME: a database of SNPs that affect protein post-translational modifications
por: Yang, Yang, et al.
Publicado: (2019)

Evaluation of polymorphisms in microRNA‐binding sites and pancreatic cancer risk in Chinese population
por: Ke, Juntao, et al.
Publicado: (2019)

CancerSplicingQTL: a database for genome-wide identification of splicing QTLs in human cancer
por: Tian, Jianbo, et al.
Publicado: (2019)

ABTB1 facilitates the replication of influenza A virus by counteracting TRIM4-mediated degradation of viral NP protein
por: Shi, Wenjun, et al.
Publicado: (2023)

Mechanism of Gegen Qinlian Decoction Regulating ABTB1 Expression in Colorectal Cancer Metastasis Based on PI3K/AKT/FOXO1 Pathway
por: Li, Feng, et al.
Publicado: (2022)

Effect of Epirubicin Plus Paclitaxel vs Epirubicin and Cyclophosphamide Followed by Paclitaxel on Disease-Free Survival Among Patients With Operable ERBB2-Negative and Lymph Node–Positive Breast Cancer: A Randomized Clinical Trial
por: Yuan, Peng, et al.
Publicado: (2023)

BRCA1 missense polymorphisms are associated with poor prognosis of pancreatic cancer patients in a Chinese population
por: Zhu, Ying, et al.
Publicado: (2017)

A genetic variant in PIK3R1 is associated with pancreatic cancer survival in the Chinese population
por: Zhu, Ying, et al.
Publicado: (2019)

A functional variant in GREM1 confers risk for colorectal cancer by disrupting a hsa-miR-185-3p binding site
por: Li, Jiaoyuan, et al.
Publicado: (2017)

A single nucleotide polymorphism in the 3′-UTR of STAT3 regulates its expression and reduces risk of pancreatic cancer in a Chinese population
por: Zhu, Beibei, et al.
Publicado: (2016)

Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer
por: Zhang, Minmin, et al.
Publicado: (2016)

A functional variant rs4442975 modulating FOXA1-binding affinity does not influence the risk or progression of breast cancer in Chinese Han population
por: Zhang, Yi, et al.
Publicado: (2016)

Neoadjuvant Ifosfamide and Epirubicin in the Treatment of Malignant Peripheral Nerve Sheath Tumors
por: Hirbe, Angela C., et al.
Publicado: (2017)

Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial
por: Zhang, Pin, et al.
Publicado: (2016)

Systematic analysis on expression quantitative trait loci identifies a novel regulatory variant in ring finger and WD repeat domain 3 associated with prognosis of pancreatic cancer
por: Zhu, Ying, et al.
Publicado: (2022)

Epirubicin
por: Cornish, J., et al.
Publicado: (1988)

Retrospective analysis of concurrent docetaxel and epirubicin neoadjuvant versus adjuvant chemotherapy: Which leads to better outcomes for different subtype breast cancer patients?
por: Yang, Houpu, et al.
Publicado: (2018)

Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer
por: Li, Qing, et al.
Publicado: (2020)

The Efficacy and Toxicity of Neoadjuvant Chemotherapy Regimens of Epirubicin Plus Cyclophosphamide Followed by Docetaxel or Paclitaxel in Female Breast Cancer Patients
por: Wu, Xian, et al.
Publicado: (2021)

Efficacy of Neoadjuvant Chemotherapy with Epirubicin and Cyclophosphamide and Weekly Paclitaxel and Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Carcinoma: A Real-World Study
por: Zhang, Mengmeng, et al.
Publicado: (2020)

Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial
por: Huang, Liang, et al.
Publicado: (2015)

Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: efficacy and safety in a prospective, randomized, phase II study
por: Chen, Jianghao, et al.
Publicado: (2013)

Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer.
por: Melcher, A. A., et al.
Publicado: (1996)

Clinical outcome and predictive factors for docetaxel and epirubicin neoadjuvant chemotherapy of locally advanced breast cancer
por: Won, Hye Sung, et al.
Publicado: (2020)

Exome-wide analysis identifies three low-frequency missense variants associated with pancreatic cancer risk in Chinese populations
por: Chang, Jiang, et al.
Publicado: (2018)

Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world study
por: Zhang, Jin, et al.
Publicado: (2021)

A Phase II Trial of Neoadjuvant Chemotherapy with Genexol® (Paclitaxel) and Epirubicin for Locally Advanced Breast Cancer
por: Lee, Jinsun, et al.
Publicado: (2014)

Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34
por: Bartsch, Rupert, et al.
Publicado: (2021)

Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast cancer: a single-arm phase II trial
por: Wang, Chengzheng, et al.
Publicado: (2023)

Circulating microRNAs as indicators in the prediction of neoadjuvant chemotherapy response in luminal B breast cancer
por: Zhang, Zhuo, et al.
Publicado: (2021)

Primary Tumor Surgery for Patients with De Novo Stage IV Breast Cancer can Decrease Local Symptoms and Improve Quality of Life
por: Si, Yiran, et al.
Publicado: (2020)

Neoadjuvant Sequential Docetaxel Followed by High‐Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial
por: Pizzuti, Laura, et al.
Publicado: (2016)

Melatonin protects against Epirubicin-induced ovarian damage
por: WANG, Naiqiang, et al.
Publicado: (2019)

Study on the infusion-site adverse events and vascular distribution of epirubicin in chemotherapy with epirubicin and fosaprepitant
por: Yamasaki, Miho, et al.
Publicado: (2019)

Efficacy and Safety of Epirubicin Combined with Temozolomide for Treatment of Advanced Leiomyosarcoma
por: Tan, Huijing, et al.
Publicado: (2021)

Evaluation of Epirubicin in Thermogelling and Bioadhesive Liquid and Solid Suppository Formulations for Rectal Administration
por: Lo, Yu-Li, et al.
Publicado: (2013)

Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial
por: Yang, Houpu, et al.
Publicado: (2022)

Immediate breast reconstruction with omental flap for luminal breast cancer patients: Ten clinical case reports
por: Li, Nanlin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4qo4ck64o64oqs8j285m7k2e3l